Shows
HemaSphere PodcastEpisode 3.1 - Single‐cell DNA and surface proteinIn this episode of the HemaSphere podcast, host Charles De Bock engages with HemaSphere Editor in Chief Professor Jan Cools, Professor Heidi Segers, and Doctor Margo Aertgeerts to discuss their recent study on acute lymphoblastic leukemia (ALL). They explore the advancements in treatment, particularly for high-hyperdiploid ALL, the challenges of relapse, and the innovative use of single cell sequencing to uncover insights into genetic mutations and clonal composition. The conversation delves into the implications of RAS mutations, the technical challenges of analyzing rare cell populations, and the future of integrating transcriptomics with single cell analysis to enhance understanding and...2025-05-0634 minHemaSphere PodcastEpisode 2.8 - Two distinct fetal-type signatures characterize JMMLIn this episode of the HemaSphere podcast, host Charles de Bock engages with Professor Hélène Cavé and Dr. Marion Strullu to discuss their recent study on juvenile myelomonocytic leukemia (JMML). They delve into the complexities of diagnosing JMML, the genetic mutations associated with the disease, and the prognostic factors that influence patient outcomes. The conversation explores the intriguing biology of JMML, including the role of transcriptional signatures and methylation patterns, as well as the challenges faced in sample collection. The episode concludes with insights into future research directions in understanding JMML. "Two distinct fetal-type signatures char...2025-04-0236 minHemaSphere PodcastEpisode 2.7 - Revolutionizing Pediatric Cancer Research with PDXsIn this episode of the HemaSphere podcast, host Dr Charles de Bock discusses the critical role of mouse models in understanding leukemogenesis and hematopoiesis with Prof Richard Lock. They explore the significance of patient-derived xenografts (PDXs) in preclinical testing, the challenges faced in generating PDXs for acute myeloid leukemia (AML), and the importance of molecular characterization. The conversation also covers the objective response criteria in drug testing, the innovative single mouse trial approach, and the future of immunotherapy testing in PDX models. Revolutionizing Pediatric Cancer Research with PDXs is on our website and all major podcast platforms...2025-02-0535 minHemaSphere PodcastEpisode 2.6 - High 5hmC predicts worse OSIn this episode of the HemaSphere podcast, host Charles de Bock discusses the latest research on myelodysplastic syndrome (MDS) with Dr Francesca Tiso and Dr Florentien in 't Hout from Radboud University Medical Center, co-authors of a recent paper published in HemaSphere. The conversation covers the clinical presentation of MDS, treatment options, and the significance of genetic mutations. Delve into their study on the prognostic value of hydroxymethylation levels in patients treated with azacitidine, highlighting the challenges of risk stratification and patient recruitment. They also discuss future research directions and the comparative efficacy of azacitidine and decitabine.“Hi...2025-01-0725 minHemaSphere PodcastEpisode 2.5 - Informed consent is almost impossibleThis podcast episode delves into the complexities of informed consent in healthcare, particularly in the context of hematology. The discussion with host Dr Charles de Bock features insights from Dr Stephen Hibbs and Dr Louise Caldwell, authors of the HemaTopics "Informed consent is almost impossible” and guest Mark Dawson, a patient family member, exploring the emotional, legal, and ethical dimensions of consent. Key themes include the variability of consent across jurisdictions, the impact of time pressures on communication, and the importance of trust in the clinician-patient relationship. The conversation also addresses the challenges posed by genetic testing and the ne...2024-11-2739 minHemaSphere PodcastEpisode 2.4 - Best of Pediatric Hematology from EHA2024In the latest episode, Dr Charles de Bock talks with Prof H. Josef Vormoor and Dr Maria Ester Bernardo, Chair and Co-Chair of EHA’s Pediatric Hematology Specialized Working Group. They discuss highlights from the EHA 2024 Congress in Madrid, including key lectures, new insights and what they could mean for clinicians, researchers, patients and their families, along with hopes and expectations for the EHA2025 Congress in Milan. “Best of Pediatric Hematology from EHA2024”, is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) and our YouTube channel. Listen and enjoy casual, insightful discussions about...2024-10-2542 minHemaSphere PodcastEpisode 2.3 - NOTCH1 fusions in T‐LBLAuthors of this recent HemaSphere published paper discovered a high-risk subgroup of pediatric T-LBL, defined by NOTCH1 gene fusions. This finding will have an important impact on newly diagnosed children with T-LBL globally, listen to two of the co-authors, Dr Jan Loeffen and Professor Roland Kuipers discuss their findings with Dr Charles de Bock, how they discovered them, and dreams of future developments in this HemaSphere podcast episode.NOTCH1 fusions in T‐LBL, is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) including YouTube Listen and enjoy casual, insightful discussions ab...2024-10-0323 min
VJHemOnc PodcastA focus on the use of artificial intelligence to personalize blood cancer careWelcome to the final episode of VJHemOnc’s Blood Cancer Awareness Month special series!
This episode focuses on the role of artificial intelligence (AI) in personalizing blood cancer care. Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses the value of AI in hematological oncology and how it is currently used in the clinic. He then shares details of a treatment infection model for chronic lymphocytic leukemia (CLL) that has been deployed in his institution. Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York City, NY, delves into the role of AI in the classification of...2024-09-3028 minHemaSphere PodcastEpisode 2.2 - A transcriptional cofactor‐mediated dependency moduleIn this newest podcast episode, Dr Charles de Bock hosts Dr Thomas Mercher and Dr Alexandre Fagnan. This episode is based on their recent paper, “The ETO2 transcriptional co-factor maintains acute leukemia by driving a MYB/EP300-dependent stemness program”, highlighting ETO2 activated gene transcription and how this affects erythroleukemia. The discussion traces the journey from part of Dr Fagnan’s PhD project (2022 EHA Junior Grant awardee), the findings in the paper and what may lie beyond. This episode is also available on our YouTube channel .Listen and enjoy casual, insightful discussions about #hematology research. Y...2024-07-3024 minHemaSphere PodcastEpisode 2.1 - Unraveling the secrets of thrombopoiesisWelcome to Season 2 of our podcast! In this episode, Dr. Francesca Vinchi interviews Professor Alessandra Balduini about thrombopoiesis. They explore Prof. Balduini's journey into research, her intuition that led to silk scaffolding, and her hopes on future results."Unraveling the secrets of thrombopoiesis", is on our website and all major podcast platforms (Spotify, Apple Podcast, YouTube, etc). Listen and enjoy casual, insightful discussions about #hematology research. You can find the referenced article, "Targeting Bone Marrow Mechanosensation in Myelofibrosis." in full and open access, here on the HemaSphere website. 2024-07-0225 minHemaSphere PodcastEpisode 1.8 - What’s so Great About the P-value? A Statistician’s Point of ViewDr Stephen Hibbs invites HemaSphere Associate Editor Prof Robert K Hills to discuss statistics in scientific writing in an entertaining and informative episode: What’s so Great About the P-value? A Statistician’s Point of View. This discussion covers the overlap of statistics and hematology with themes like the importance of P value and the use of statistics in clinical trials.What’s so Great About the P-value? A Statistician’s Point of View, is on our website , all major podcast platforms (Spotify, Apple Podcast, etc), and YouTube. Listen and enjoy casual, insightful discussions about #hematology re...2023-12-0630 min
EHA UnpluggedThe Whats in Scientific PublishingIn this episode, join HemaSphere's editor-in-chief, Prof Jan Cools, as he guides you through article publishing. Acquire valuable insights, tips, and new perspectives on often-overlooked considerations. Prof Cools sheds light on the pivotal role of reviewers in the publishing process and provides his insights into the evolving impact of AI on publishing.Guest: Prof Jan Cools, KU Leuven. Belgium. Editor-in-Chief of HemaSphereHost: Dr Wilson Lim, European Hematology Association (EHA)Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback...2023-12-0120 minEHA UnpluggedUnraveling Autoimmune Neutropenia: From Childhood to AdulthoodJoin us for this update on Autoimmune Neutropenia (AIN), a rare blood disorder that presents and develops differently in children and adults. Experts Dr Francesca Fioredda and Prof Helen Papadaki along with our host Dr. Isabel Olivera discuss the diagnostic challenges associated with AIN and the need for a broader definition, based on the latest insights from the different mechanisms underlying AIN’s pathogenesis.Learn how to adapt the treatment of AIN to the specific form of neutropenia, the patient’s age, evolving needs, and underlying disease. Our experts also emphasize the importance of ca...2023-11-0321 minHemaSphere PodcastEpisode 1.7 - This Is Going to Hurt: Revisiting the Patient Experience of Bone Marrow BiopsiesDr Stephen Hibbs invites Dr Joseph Taylor to a discussion based on Dr Hibbs popular HemaTopics article, This Is Going to Hurt: Revisiting the Patient Experience of Bone Marrow Biopsies. The conversation ranges from the type of training providers receive, how to talk to patients about these bone marrow biopsies, and some of the outstanding questions about bone marrow biopsies and the patient experience. This Is Going to Hurt: Revisiting the Patient Experience of Bone Marrow Biopsies, is on our website, all major podcast platforms (Spotify, Apple Podcast, etc), and YouTube. You can find the referenced article, in...2023-11-0224 minHemaSphere PodcastEpisode 1.6 - The European Guidelines on Diagnosis and Management of Neutropenia in Adults and ChildrenThough many advances have been made in neutropenias, diagnosis and management are still based on physicians’ experience or local practices. Prof Francesca Fioredda and Prof Helen Papadaki, two co-authors of the HemaSphere published article The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action, discuss with host Dr Stephen Hibbs the challenges and outcomes in creating a guideline for diagnosis and managing neutropenia in adults and children. Read the referenced article on the HemaSphere website and watch on YouTube.2023-10-0527 minHemaSphere PodcastEpisode 1.4, Part 1 - Comprehensive Diagnosis and Management of POEMS SyndromePOEMS syndrome (Polyneuropathy Organomegaly, Endocrinopathy, M-protein and Skin changes) is rare, and systemic manifestations are commonly overlooked initially. Diagnosis is often delayed 12-16 months, during which patients can be severely disabled. No established treatment guidelines exist for POEMS. A recent HemaSphere published article, Comprehensive Diagnosis and Management of POEMS Syndrome, offers a clinical blueprint for managing POEMS, from diagnostics to work-up, therapy selection, follow-up, and relapse treatment. Shirley d'Sa & Michael Lunn, two co-authors of the article discuss with host Dr Stephen Hibbs, in this first of 2 episodes, why multidisciplinary collaboration is essential. Continue with Part 2 here. 2023-09-0723 minHemaSphere PodcastEpisode 1.5, Part 2 - Comprehensive Diagnosis and Management of POEMS SyndromePOEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, M-protein and Skin changes) is rare, and systemic manifestations are commonly overlooked initially. Diagnosis is often delayed 12-16 months, during which patients can be severely disabled. No established treatment guidelines exist for POEMS. A recent HemaSphere published article Comprehensive Diagnosis and Management of POEMS Syndrome offers a clinical blueprint for managing POEMS, from diagnostics to work-up, therapy selection, follow-up, and relapse treatment. Shirley d'Sa & Michael Lunn, two co-authors of the article discuss with host Dr Stephen Hibbs, in this second of two episodes, why multidisciplinary collaboration is essential. Catch up with Part 1 h...2023-09-0724 minHemaSphere PodcastEpisode 1.3 - Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of MyelofibrosisMachine Learning is a subsection in thefield of Artificial Intelligence. How can this be used as a tool in hematology-oncology for advanced disease prognostification and beyond? Adrián Mosquera-Orgueira and Juan Carlos Hernández-Boluda, two co-authors of the HemaSphere published article Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis, discuss with host Dr Stephen Hibbs the challenges and outcomes in utilizing a novel myelofibrosis survival model that aids in risk stratification for patients diagnosed with myelofibrosis. Read the referenced article in HemaSphere, also available on our YouTube channel.2023-08-0234 minHemaSphere PodcastEpisode 1.2 - EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With CancerAs the overall cancer death rate has declined over past decades and cancer survival has increased, unforeseen challenges are emerging. Thrombocytopenia, often associated with cancer disease or anticancer therapy, will be more present in thrombotic cancer patients, but evidence on how to treat these patients is lacking. Prof Anna Falanga discusses these Guidelines with host Dr Stephen Hibbs in this HemaSphere Podcast episode. You can find the referenced article, in full and open access, here on the HemaSphere website, or watch the video on our YouTube channel. 2023-07-0624 minHemaSphere PodcastEpisode 1.1 - “Long COVID-19” of Researchers: What to Do Next?What to do next for “Long COVID-19” of researchers? A survey from scientists toscientists led by the Young European Hematology Association (Young EHA)committee led tothis discussion about how COVID-19 impacted researchers, especially earlier intheir career and without a network. What tools did they discover to get throughit? Find it on the HemaSphere website, “Long COVID-19” of Researchers: What to Do Next? , or watch on our YouTube channel. 2023-06-0820 minEHA UnpluggedPapers Unplugged: The Perspectives of Doctors and Patients in the Treatment of CLLJoin Prof Paolo Ghia and our host Dr Enrica Orsini as they discuss the treatment of Chronic Lymphocytic Leukemia (CLL) from the perspectives of patients and doctors.In this episode, they discuss the factors that influence the decision of treatment choices from the perspectives of patients and doctors and how both parties have different perspectives on the subject. They further highlight the importance of understanding the differing priorities between these two groups and the need for shared decision-making in the treatment process.The podcast is based on the paper: "What Are the Attributes Prioritized in the...2023-03-1709 minEHA UnpluggedPapers Unplugged: What's New in the Treatment of CLL?In this podcast, Prof Paolo Ghia discusses the current treatment landscape of Chronic Lymphocytic Leukemia (CLL), providing a guide for clinicians faced with an ever-growing number of therapeutic alternatives. Within targeted therapies, a special focus is dedicated to BTK inhibitors and their different characteristics, and to the long-term results of the ASCEND trial. The management of CLL is changing rapidly, and Prof Ghia's expertise can help hematologists to choose the right treatment for their patients, even in high-risk cases, such as the ones with TP53 mutation or del(17p).The podcast is...2023-02-1011 minEHA UnpluggedPapers Unplugged: TIF Guidelines for the Management of Patients with Transfusion-Dependent Thalassemia (TDT)What are the latest guidelines for the management of patients with Transfusion-Dependent Thalassemia (TDT)?In 2022, the fourth edition of the TIF (Thalassemia International Federation) guidelines for the management of patients with transfusion-dependent thalassemia (TDT) was published. In this podcast, Prof Ali Taher discusses with our host, Dr Nathalie van Havre, the main news of this edition, including genetic work-up, chelation therapy, and prevention and management of complications.Furthermore, Prof Taher illustrates the innovative gene therapy approaches and new drugs (such as luspatercept, the most recently approved drug for TDT) currently...2023-01-2716 minEHA UnpluggedPapers Unplugged: Is CAR-T Economically Sustainable?Is CAR-T economically sustainable?Join our guest Prof Martin Dreyling and host Dr Nathalie van Havre as they discuss the costs of CAR-T cell therapy for the treatment of blood disorders at an individual level and whether it is economically sustainable for health systems.Listen along as they consider the financial challenges of patient selection for this costly life-saving therapy, based on Prof Dreyling’s experience with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) patients. Challenges touched upon include reimbursement policies, time lags and associated costs of personalized therapy, and choosing the indications to in...2023-01-1317 minEHA UnpluggedPapers Unplugged: What Ever Happened to Plan S?What is Plan S and what has happened to it?Join our guest Dr Nuno Borges and host Dr Christian Scharenberg as they talk about the core principles, goals, and challenges of Plan S.Listen along as Dr Borges discusses the controversies aroused by Plan S and the “publish or perish” paradigm faced by early career scientists. Dr Borges ends this podcast on a positive note where he believes that slowly, but surely, and thanks to social media, we are heading towards a future where scientific publications will be open access and freely available to ever...2022-12-0907 minEHA UnpluggedPapers Unplugged: CHIP and Associated Risk in Elderly PatientsWhat is clonal hematopoiesis of indeterminate potential (CHIP) and its associated risks in elderly patients?Join our guest Prof Kirsten Gronbaek and host Dr Christian Scharenberg as they discuss CHIP, its biological significance, frequency in the general population, and its association with epigenetic age. Listen along as Prof Gronbaek dives deeper into the subject and explains the association and significance of CHIP with mutations and patient survival. Last but not least, Prof Gronbaek talks about the challenges and current landscape of trials and studies on treatment for CHIP.This discussion is based on...2022-11-2508 minEHA UnpluggedPapers Unplugged: EHA and War in UkraineWhat can a not-for-profit NGO do for patients in a time of war? Join our guests, Prof Konstanze Döhner, Prof Elizabeth Macintyre, and Dr Nathalie van Havre as they discuss what the European Hematology Association (EHA) has done in favor of Ukraine and the Ukrainian hematological community. Our guests talk about support programs EHA has implemented and the obstacles that came with that. Prof Macintyre furthers the discussion by expressing her views on the role of medical organizations such as EHA in a crisis. This discussion is based on t...2022-11-1112 minEHA UnpluggedPapers Unplugged: Precision Medicine and HemoglobinopathiesJoin our guest Prof David Rees and host Dr Christian Scharenberg as they discuss how the concept of precision medicine can be applied to Sickle Cell Disease (SCD).Listen as Prof David Rees talks about prognostic markers and how they can (or can't) guide SCD disease management, current and new treatment options for SCD patients, and how the situation of precision medicine can differ between low- and high-income countries. Last but not least, Prof David Rees ends the podcast with his view of how SCD management will be in the near and far future.This...2022-10-2811 min